---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-202430"
form_type: "8-K"
ticker: "ANTX"
cik: "0001880438"
company_name: "AN2 Therapeutics, Inc."
filed_at: "2024-08-19T23:59:59+00:00"
generated_at: "2026-05-31T08:43:43.356770+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# AN2 Therapeutics adopts limited-duration stockholder rights plan after BML accumulates 19.3% stake

## Summary
- Rights plan triggered by rapid accumulation of 19.3% of ANTX common stock by BML Investment Partners, as disclosed in Aug. 14, 2024 13G/A filing.
- One preferred stock purchase right distributed per common share held on Aug. 29, 2024; exercise price $6.50 per one-thousandth of Series A Preferred.
- Rights become exercisable if a person or group acquires 20% or more of common stock (including synthetic ownership).
- Rights expire Aug. 15, 2025, unless earlier redeemed ($0.01 per right) or exchanged by Board.
- Plan designed to protect all stockholders and prevent coercive takeover tactics without paying a control premium.

## SEC filing metadata
- accession: 0001193125-24-202430
- form_type: 8-K
- ticker: ANTX
- cik: 0001880438
- company_name: AN2 Therapeutics, Inc.
- filed_at: 2024-08-19T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 3.03, 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1880438/000119312524202430/0001193125-24-202430-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1880438/000119312524202430/d879523d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-202430
- JSON: https://secwatch.observer/filing/0001193125-24-202430.json
- Plain text: https://secwatch.observer/filing/0001193125-24-202430.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.